CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer is a phase 2, randomised interventional study registered as NCT07383285 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 106 participants, started 2026-02-01 and due to reach its primary completion in 2029-12-31. Interventions recorded: Iparomlimab and Tuvonralimab; Radiotherapy to the primary site; Capecitabine; Bevacizumab; Oxaliplatin injection. Conditions listed: Rectal Neoplasms Malignant. Primary outcome: 12-month disease-free survival rate (progression-free survival rate, PFSR). Colorectal eligibility wording from the registry: "Pathological tissue diagnosis confirmed rectal adenocarcinoma (including signet ring cell carcinoma and mucinous adenocarcinoma);". No results are recorded here; the registry entry is the source.